Overview

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This Phase 1/2a study is intended to assess the safety, tolerability, and effects on intraocular pressure of two dose levels and two dose frequencies of LX7101 when administered topically in the eyes of patients diagnosed with primary open-angle glaucoma or ocular hypertension.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Lexicon Pharmaceuticals